单克隆抗体
奥沙利铂
细胞凋亡
癌症研究
体内
免疫印迹
活力测定
癌细胞
体外
抗体
化学
癌症
医学
免疫学
生物
生物化学
内科学
结直肠癌
生物技术
基因
作者
Fengyong Wang,Yihong Sun,Jianfeng Shi
出处
期刊:Nanomedicine
日期:2019-07-01
卷期号:14 (13): 1729-1744
被引量:15
标识
DOI:10.2217/nnm-2019-0073
摘要
Aim: PD-L1 monoclonal antibody-conjugated miR-130a/oxaliplatin-loaded immunoliposomes were constructed for enhanced therapeutic efficacy against gastric cancer. Materials & methods: The in vitro antitumor efficacy of the immunoliposomes was evaluated by cell viability, cell invasion, cell apoptosis and western blot analysis and in vivo antitumor efficacy was evaluated in a HGC27-bearing tumor xenograft model. Results: The inhibitory role of miR-130a was demonstrated in HGC27 cells by the downregulation of RAB5A and FOCL1 signaling pathways. Consequently, PD-miOXNP exhibited the strongest anticancer activity in vitro compared with any other formulation. PD-miOXNP showed a significantly higher anticancer efficacy in HGC27 tumors with reduced Ki67 + cells and increased TUNEL + cells for mice group. Conclusion: PD-L1 monoclonal antibody-conjugated immunoliposomes have immense potential to be applied as a next-generation nanomedicine for PD-L1-positive gastric cancers.
科研通智能强力驱动
Strongly Powered by AbleSci AI